Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  10.00 0.33% 3,035.00 817 15:35:51
Bid Price Offer Price High Price Low Price Open Price
3,020.00 3,050.00 3,035.00 3,025.00 3,025.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.31 8.23 139.41 21.8 158
Last Trade Time Trade Type Trade Size Trade Price Currency
15:35:51 O 1 3,050.00 GBX

Bioventix (BVXP) Latest News

More Bioventix News
Bioventix Investors    Bioventix Takeover Rumours

Bioventix (BVXP) Discussions and Chat

Bioventix Forums and Chat

Date Time Title Posts
20/1/202212:10Bioventix - Sheep Antibodies1,404
08/11/201613:07ShareSoc Supper in Brighton-

Add a New Thread

Bioventix (BVXP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-01-26 15:35:513,050.00130.50O
2022-01-26 14:44:513,045.002016,120.45O
2022-01-26 14:09:343,022.5037011,183.25O
2022-01-26 14:06:333,022.50792,387.78O
2022-01-26 13:37:173,007.00130.07O
View all Bioventix trades in real-time

Bioventix (BVXP) Top Chat Posts

Bioventix Daily Update: Bioventix Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 3,025p.
Bioventix Plc has a 4 week average price of 3,025p and a 12 week average price of 3,025p.
The 1 year high share price is 4,500p while the 1 year low share price is currently 2,260p.
There are currently 5,209,333 shares in issue and the average daily traded volume is 13,088 shares. The market capitalisation of Bioventix Plc is £158,103,256.55.
tmfmayn: BIOVENTIX: FY 2021 Results Unveil Record H2 Profit (+14%) While Finite Troponin Income Shifts Longer-Term Perspective Towards Pyrene Project And Alzheimer’s Research #BVXP
 "Valuing the pipeline at a negative £5m seems about right if annual R&D costs are £1.2m and research commercialisation is not expected until 2025 at the earliest" hTTps://maynardpaton.com/2021/11/05/bioventix-fy-2021-results-unveil-record-h2-profit-14-while-finite-troponin-income-shifts-longer-term-perspective-towards-pyrene-project-and-alzheimers-research/
jonut: Full list of bvxp rns's here, https://www.investegate.co.uk/Index.aspx?searchtype=3&words=bvxp
gnnmartin: I hoped to find the latest BVXP presentation to investors, but I can't find anything later that 2019. I expected to find it on the BVXP web site, but that gives surprisingly little information. Can anyone tell me where I can find what I seek?
vprt: You're welcome; great if you get full clarity on this point - please share if you do.
stepone68: I suppose the key thing is that there is 1.2m of revenue which will not be in future results. Troponin is roughly half of that level. Even if it doubles again this year, we will be down overall, so we need Vitamin D to return to growth. There are a lot of things I like about this company - the long royalty terms, the simple results, the low cost of sales, being in the healthcare sector, the dividend and the quick dividend turn around time (ex divi next week and paid 2 weeks later). But it is highly rated so I think share price growth will be limited from here on (unless Troponin really takes off).
shouldhavesold: That’s daft. It’s the yield on current price that’s the only thing worth considering Otherwise how do you compare with alternatives for your money etc. You could have an investment 50yrs old paying 5000% on your purchase price - means nothing if it’s 1% on the current value Compare like with like Look to the future, not the past The yield here is good though
apad: I paid 3854p for BVXP this morning. Averaging up, so my yield will reduce 😊 My thinking was that I expected them to be suffering more than they are and previously they have been marked down on opening only to recover as folks find something to be pleased about. Anyroadup they are 3910 to buy at the moment, so not much of an effect. apad BTW I have also observed them being marked down on the ex div morning and then ambling up during the day.
stepone68: It's fine to talk about yield on your purchase price but you should also value your holding at that price. Otherwise you are trying to have your cake and eat it.
apad: My average buying price yield. Bought some more this morning. apad
apad: BVXP troponin sales doubled. Maybe this is a significant increase given the state of hospitals. No comment on the Point of Care tests as a competitor. Easy to hold on a 7% yield. "Over the next few years, the commercial development of the new troponin assays will have the most significant influence on Bioventix sales. There are currently no antibodies in the future pipeline that are comparable to our troponin products in potential value and the ability to influence revenues in the next few years." apad
Bioventix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220127 00:19:48